CDKN2A and sarcoma: In comparison with data regarding PATZ1-fused sarcoma, the PATZ1-fused CNS tumors in this series were not enriched for homozygous deletions mapping to the CDKN2A/B locus (observed in only 2/59 cases, 3%) [3].